SOLS Stock Analysis: Solstice Advanced Materials | NASDAQ

Specialty Chemicals | NASDAQ, USA | Market Cap: 9.952m USD | 12M Return: 16.3% | US83443Q1031 | Charts, Fundamentals & Technical Analysis

Refrigerants, Electronic Materials, Industrial Fibers, Life Science Chemicals
Total Rating 43
Safety 59
Buy Signal -0.23
Specialty Chemicals
Industry Rotation: +1.7
Market Cap: 9.95B
Avg Turnover: 147M
Risk 3d forecast
Volatility56.3%
VaR 5th Pctl9.58%
VaR vs Median3.34%
Reward TTM
Sharpe Ratio0.52
Rel. Str. IBD10.3
Rel. Str. Peer Group28.1
Character TTM
Beta0.634
Beta Downside1.785
Hurst Exponent0.480
Drawdowns 3y
Max DD37.18%
CAGR/Max DD0.53
CAGR/Mean DD2.18
EPS (Earnings per Share) EPS (Earnings per Share) of SOLS over the last years for every Quarter: "2022-12": null, "2023-12": null, "2024-06": null, "2024-09": null, "2024-12": null, "2025-03": null, "2025-06": 0.7236, "2025-09": 0.5473, "2025-12": 0.26, "2026-03": 0.63, "2026-06": 0.88,
Last SUE: 0.24
Qual. Beats: 0
Revenue Revenue of SOLS over the last years for every Quarter: 2022-12: 3587, 2023-12: 3649, 2024-06: 975, 2024-09: 907, 2024-12: 913, 2025-03: 897, 2025-06: 1033, 2025-09: 969, 2025-12: 987, 2026-03: 991, 2026-06: 1148,
Rev. CAGR: 3.20%
Rev. Trend: 100.0%
Qual. Beats: 0

Warnings

Below Avwap Earnings
Below Sma 200d

Tailwinds

Confidence

Seasonality 1.6 years of data

Jan - -
Feb - -
Mar - -
Apr - -
May - -
Jun - -
Jul - -
Aug - -
Sep - -
Oct - -
Nov - -
Dec - -

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: SOLS Solstice Advanced Materials

Solstice Advanced Materials, Inc. (NASDAQ: SOLS) is a U.S.-headquartered specialty chemicals and advanced materials company that operates through two segments: Refrigerants & Applied Solutions (RAS) and Electronic & Specialty Materials (ESM). The RAS segment produces low global-warming-potential (LGWP) refrigerants, blowing agents, solvents, and aerosol materials marketed under the Solstice, Genetron, and Aclar brands, while the ESM segment supplies electronic materials, high-strength fibers, and life-science chemicals for semiconductor, defense, pharmaceutical, and construction end-markets under the Spectra, Fluka, and Hydranal brands. The company recently completed its IPO on October 29, 2025, and is incorporated and headquartered in Morris Plains, New Jersey.

As a specialty chemicals producer, Solstice focuses on differentiated, formulation-intensive products rather than high-volume commodity chemicals, which generally supports higher margins but exposes results to feedstock volatility. Its LGWP refrigerant portfolio is positioned to benefit from regulatory phase-downs of high-GWP HFCs under frameworks such as the U.S. AIM Act and the Kigali Amendment, while its semiconductor and life-science materials businesses target end-markets with structural demand growth tied to electronics manufacturing and pharmaceutical research.

Headlines to Watch Out For
  • AIM Act mandates accelerate low-GWP refrigerant adoption
  • Semiconductor sputtering target demand tracks AI chip capex
  • Pharma packaging Aclar sales grow with biologics expansion
Piotroski VR-10 (Strict) 4.0
Net Income: 210.0m TTM > 0 and > 6% of Revenue
FCF/TA: 0.03 > 0.02 and ΔFCF/TA -6.50 > 1.0
NWC/Revenue: 19.73% < 20% (prev 15.68%; Δ 4.05% < -1%)
CFO/TA 0.10 > 3% & CFO 606.0m > Net Income 210.0m
Net Debt (1.77b) to EBITDA (891.0m): 1.99 < 3
Current Ratio: 1.46 > 1.5 & < 3
Outstanding Shares: last quarter (159.3m) vs 12m ago 0.37% < -2%
Gross Margin: 30.62% > 18% (prev 34.85%; Δ -4.23% > 0.5%)
Asset Turnover: 74.54% > 50% (prev 73.96%; Δ 0.57% > 0%)
Interest Coverage Ratio: 8.71 > 6 (EBIT TTM 671.0m / Interest Expense TTM 77.0m)
Altman Z'' 2.22
A: 0.14 (Total Current Assets 2.57b - Total Current Liabilities 1.76b) / Total Assets 5.92b
B: 0.04 (Retained Earnings 220.0m / Total Assets 5.92b)
C: 0.12 (EBIT TTM 671.0m / Avg Total Assets 5.49b)
D: 0.37 (Book Value of Equity 1.59b / Total Liabilities 4.33b)
Altman-Z'' = 2.22 = BBB
Beneish M -2.70
DSRI: 1.37 (Receivables 985.0m/659.0m, Revenue 4.09b/3.75b)
GMI: 1.14 (GM 34.85% / 30.62%)
AQI: 0.72 (AQ_t 0.21 / AQ_t-1 0.29)
SGI: 1.09 (Revenue 4.09b / 3.75b)
TATA: -0.07 (NI 210.0m - CFO 606.0m) / TA 5.92b)
Beneish M = -2.70 (Cap -4..+1) = A
What is the price of SOLS shares?

As of August 23, 2026, the stock is trading at USD 56.16 with a total of 2,051,627 shares traded. Over the past week, the price has changed by -10.36%, over one month by -6.52%, over three months by -29.19% and over the past year by +16.25%.

Current recommended Stop Loss: 50.60 (which is 9.9% or 2 ATR below the current price).

Is SOLS a buy, sell or hold?

Solstice Advanced Materials has no consensus analysts rating.

Solstice Advanced Materials (SOLS) - Fundamental Data Overview as of 17 August 2026
Market Cap USD = 9.95b (9.95b USD * 1.0 USD.USD)
P/E Trailing = 47.4621
P/E Forward = 21.5983
P/S = 2.4302
P/B = 6.2748
P/EG = 0.6946
Revenue TTM = 4.09b USD
EBIT TTM = 671.0m USD
EBITDA TTM = 891.0m USD
Long Term Debt = 1.98b USD (from longTermDebt, last quarter)
Short Term Debt = 350.0m USD (from shortTermDebt, last quarter)
Debt = 2.52b USD (from shortLongTermDebtTotal, last quarter) + Leases 109.0m
Net Debt = 1.77b USD (calculated: Debt 2.52b - CCE 750.0m)
Enterprise Value = 11.7b USD (9.95b + Debt 2.52b - CCE 750.0m)
Interest Coverage Ratio = 8.71 (Ebit TTM 671.0m / Interest Expense TTM 77.0m)
EV/FCF = 65.48x (Enterprise Value 11.7b / FCF TTM 179.0m)
FCF Yield = 1.53% (FCF TTM 179.0m / Enterprise Value 11.7b)
FCF Margin = 4.37% (FCF TTM 179.0m / Revenue TTM 4.09b)
Net Margin = 5.13% (Net Income TTM 210.0m / Revenue TTM 4.09b)
Gross Margin = 30.62% ((Revenue TTM 4.09b - Cost of Revenue TTM 2.84b) / Revenue TTM)
Gross Margin QoQ = 32.23% (prev 31.89%)
Tobins Q-Ratio = 1.98 (Enterprise Value 11.7b / Total Assets 5.92b)
Interest Expense / Debt = 3.06% (Interest Expense 77.0m / Debt 2.52b)
Taxrate = 23.86% (42.0m / 176.0m)
NOPAT = 510.9m (EBIT 671.0m * (1 - 23.86%))
Current Ratio = 1.46 (Total Current Assets 2.57b / Total Current Liabilities 1.76b)
Debt / Equity = 1.59 (Debt 2.52b / totalStockholderEquity, last quarter 1.59b)
Debt / EBITDA = 1.99 (Net Debt 1.77b / EBITDA 891.0m)
Debt / FCF = 9.89 (Net Debt 1.77b / FCF TTM 179.0m)
Total Stockholder Equity = 1.93b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.82% (Net Income 210.0m / Total Assets 5.92b)
RoE = 10.89% (Net Income TTM 210.0m / Total Stockholder Equity 1.93b)
RoCE = 17.17% (EBIT 671.0m / Capital Employed (Equity 1.93b + L.T.Debt 1.98b))
RoIC = 11.87% (NOPAT 510.9m / Invested Capital 4.30b)
WACC = 7.02% (E(9.95b)/V(12.5b) * Re(8.21%) + D(2.52b)/V(12.5b) * Rd(3.06%) * (1-Tc(0.24)))
Discount Rate = 8.21% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 74.23 | Cagr: 0.18%
[DCF] Terminal Value 73.10% ; FCFF base≈300.6m ; Y1≈263.6m ; Y5≈213.0m
[DCF] Fair Price = 10.38 (EV 3.42b - Net Debt 1.77b = Equity 1.65b / Shares 158.8m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.24 | # QB: 0
Revenue Correlation: 99.98 | Revenue CAGR: 3.20% | SUE: N/A | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.71 | Chg30d=+7.99% | Revisions=+62% | Analysts=6
EPS current Year (2026-12-31): EPS=2.88 | Chg30d=+8.55% | Revisions=+67% | GrowthEPS=+93.2% | GrowthRev=+7.6%
EPS next Year (2027-12-31): EPS=3.35 | Chg30d=+4.29% | Revisions=+67% | GrowthEPS=+16.2% | GrowthRev=+5.6%
[Analyst] Revisions Ratio: +85% (up=17, down=0)